Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Collaborator:
Tufts University
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Nursing Research (NINR) )
ClinicalTrials.gov Identifier:
NCT02019680
First received: December 20, 2013
Last updated: March 14, 2014
Last verified: December 2013
  Purpose

Background:

- Heart disease is the leading cause of death in the United States. Eating fruits and vegetables with chemicals called flavonoids may protect against heart disease and improve blood flow to the heart. They are found in blackcurrant berries. Oils found in fish and mussels called omega-3 fats have also been shown to protect the heart. Researchers want to know if blackcurrant extract and omega-3 fats can improve blood flow, which may increase blood to the heart. They also want to learn about the health of blood vessels and how the heart works.

Objective:

- To learn if blackcurrant extract and omega-3 fats will improve blood flow and make the heart beat stronger.

Eligibility:

- Healthy adults 55 to 75 years old.

Design:

  • Participants will be screened with medical history, physical exam, and blood tests.
  • Visit 1 will take 6 7 hours.
  • Participants will have physical exam and blood and urine tests.
  • A small device like a microphone will be placed on their arm to take pictures of blood vessels. A blood pressure cuff will be tightened on their arm and more pictures will be taken.
  • Blood pressure cuffs will be placed on their arms and legs. They will be tightened at the same time and blood pressure will be measured.
  • Participants will answer questions about their eating and exercise.
  • Every 8 weeks, participants switch from taking blackcurrant and/or omega-3 tablets to a placebo to no tablets. < TAB>
  • Every 8 weeks, they will have another shorter clinic visit that will repeat most of visit 1.

Condition
Abnormalities
Hyperlipidemia
Cardiovascular Disease
Arteriosclerosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Effects of Dietary Blackcurrant Extract and PCSO-5 PernaCanaliculus Supercritical Oil) on Endothelial Function and Biomarkers of Vascular Health

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Endothelial function (flow-mediated brachial artery dilation) and arterial stiffness (cardio-ankle vascular index) [ Time Frame: 8 weeks x 4 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Biomarkers of vascular health (endothelial dysfunction, inflammation, injury, oxidative stress, nitric oxide status), lipids and fatty acid profile, and flavonoid profiles [ Time Frame: 8 weeks x 4 ] [ Designated as safety issue: No ]

Estimated Enrollment: 102
Study Start Date: December 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Detailed Description:

Numerous studies have shown the beneficial effects of fruits, vegetables and omega-3 fatty acids in reducing the risk of cardiovascular disease. The cardioprotective properties may be attributed to the bioactive compounds found in fruits and vegetables called flavonoids. High concentrations of flavonoids with antioxidant activity are found in blackcurrant extract. Flavonoids like omega-3 fatty acids may improve vascular function by increasing the bioavailability of nitric oxide, a potent vasodilator. PCSO-524 (Pernacanaliculus supercritical oil) is of particular interest as a rich source of omega-3 fatty acids derived from the green-lipped mussel. The objectives of this study are to determine the effects of blackcurrant extract, PCSO-524 or the combination of blackcurrant extract & PCSO-524 on endothelial function (flow-mediated brachial artery dilation) and arterial stiffness (cardioankle vascular index) as indicators of cardiovascular risk and atherosclerosis. These indices also provide an assessment of structure and function of the artery. The effects of the supplements on biomarkers of vascular health (endothelial dysfunction, inflammation, injury, oxidative stress, nitric oxide status), lipids and fatty acid profile, and flavonoid profiles will also be determined. In a randomized, double-blind, placebo-controlled trial, 102 healthy older adults (ages 55-75) will be given either blackcurrant extract (1000 mg), PCSO-524 (400 mg), or blackcurrant extract (1000 mg) & PCSO-524 (400 mg) daily for 8 weeks while consuming their usual diet. The study will include 4 visits at 8 week intervals consisting of treatment, washout and placebo phases.

  Eligibility

Ages Eligible for Study:   55 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA
  • Men and women between the ages of 55-75 years
  • In general good health as determined by screening evaluation
  • Normal or pre-hypertensive blood pressure (e.g. Systolic less than or equal to 139 mm Hg and Diastolic less than or equal to 89 mm Hg
  • Normal or mild hyperlipidemia (e. g. Total Cholesterol less than or equal to 239, LDL less than or equal to 159, Triglycerides less than or equal to 199, HDL less than or equal to 40 mg/dL)
  • BMI between 18.5 to 25 kg/m
  • Willingness and ability to give consent
  • Willingness to make time commitment for the study

EXCLUSION CRITERIA

  • Progressive or unstable disease of any body system including cardiovascular, pulmonary, gastrointestinal, central nervous system, psychiatric, endocrine, hematologic, renal or immunologic disorders
  • Known acute or chronic inflammatory disease ( e.g. rheumatoid arthritis, systemic lupus erythematosus, hepatitis)
  • Elevated C-reactive protein (CRP) level > 3.0 mg/L
  • Elevated fasting blood glucose level > 120 mg/dL
  • Elevated lipid profile : Total cholesterol > 239 mg/dL, Triglycerides > 200 mg/dL, LDL > 160mg/dL
  • Abnormal complete blood count (CBC): White Blood Cell Count < 4 or > 10 K/uL, Red Blood Cell Count < 4 or > 7 M/uL, Hemoglobin < 13 or > 18 g/dL, Hematocrit < 39 or > 52%
  • Recent or ongoing alcohol or drug abuse
  • Known sensitivity or allergy to fish oil, or shell fish
  • Smoking any tobacco products (cigarettes, pipe, etc.)
  • Subjects currently taking fish oil supplements (participation is possible after 2 month washout period)
  • Subjects taking blood thinners (i.e., Coumadin, warfarin etc.)
  • Subjects with bleeding disorders (i.e., hemophilia)
  • Subjects taking cholesterol-lowering, anti-hypertensive, thyroid or hormonal medications
  • Subjects taking aspirin, non-steroidal anti-inflammatory (NSAIDS) medications or fish oil on a regular basis unless they were discontinued 14 days prior to their first visit.
  • Subjects starting cholesterol-lowering, anti-hypertensive, thyroid or hormonal medications or fish oil during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02019680

Contacts
Contact: Shashi Ravindran, R.N. (301) 496-3859 ravindrs@mail.nih.gov
Contact: Marguerite M Engler, Ph.D. (301) 496-3916 englermm@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Not yet recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Tufts University
Investigators
Principal Investigator: Marguerite M Engler, Ph.D. National Institute of Nursing Research (NINR)
  More Information

Additional Information:
Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Nursing Research (NINR) )
ClinicalTrials.gov Identifier: NCT02019680     History of Changes
Other Study ID Numbers: 140034, 14-NR-0034
Study First Received: December 20, 2013
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Endothelial Function
Biomarkers
Atherosclerosis
Blood Flow
Blood Pressure

Additional relevant MeSH terms:
Cardiovascular Diseases
Hyperlipidemias
Arteriosclerosis
Atherosclerosis
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 01, 2014